UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 56

Sortiert nach

Phase 1 trial of Ruxolitinib combined with Nivolumab in patients relapsed/refractory Hodgkin lymphoma after failure of check‐point inhibitor (CPI)

Hematological oncology, 2023-06, Vol.41 (S2), p.582-582

2023

Volltextzugriff (PDF)

Responses after Allogeneic NK Cell Therapy for Lymphoma: correlative analysis revealed impact of host monocytes and robust T cells tumor trafficking

Hematological oncology, 2023-06, Vol.41 (S2), p.518-519

2023

Volltextzugriff (PDF)

Leg ulcers in patients with β-thalassaemia intermedia: a single centre's experience

Journal of the European Academy of Dermatology and Venereology, 2014-09, Vol.28 (9), p.1245-1250

2014

Volltextzugriff (PDF)

Intracranial blood flow velocities in patients with sickle cell disease and β‐thalassemia intermedia

American journal of hematology, 2013-09, Vol.88 (9), p.825-825

2013

Volltextzugriff (PDF)

PHASE I DOSE‐ESCALATION STUDY OF VENETOCLAX PLUS BEAM FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) FOR CHEMORESISTANT, RELAPSED/REFRACTORY, OR HIGH‐RISK NON‐HODGKIN'S LYMPHOMA (NHL); PRELIMINARY RESULTS

Hematological oncology, 2019-06, Vol.37 (S2), p.528-529

2019

Volltextzugriff (PDF)

A puzzling mutation in congenital erythropoietic porphyria and an association with β-thalassaemia trait

British journal of dermatology (1951), 2012-09, Vol.167 (3), p.697-699

2012

Volltextzugriff (PDF)

A phase II trial of brentuximab vedotin (BV) and lenalidomide (Len) in relapsed and refractory (r/r) cutaneous (CTCL) and peripheral (PTCL) T-cell lymphomas

European journal of cancer (1990), 2019, Vol.119, p.S28

2019

Volltextzugriff (PDF)

077 - A phase II trial of brentuximab vedotin (BV) and lenalidomide (Len) in relapsed and refractory (r/r) cutaneous (CTCL) and peripheral (PTCL) T-cell lymphomas

European journal of cancer (1990), 2019, Vol.119, p.S28-S28

2019

Volltextzugriff (PDF)

17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023

Hematological oncology, 2023-06, Vol.41 Suppl 2, p.582

2023

Volltextzugriff (PDF)

An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis

Bone marrow transplantation (Basingstoke), 2021-12, Vol.56 (12), p.3068-3077

2021

Volltextzugriff (PDF)

Cytopenias After CD19 Chimeric Antigen Receptor T-Cells (CAR-T) Therapy for Diffuse Large B-Cell Lymphomas or Transformed Follicular Lymphoma: A Single Institution Experience

Cancer management and research, 2021-01, Vol.13, p.8901-8906

2021

Volltextzugriff (PDF)

A puzzling mutation in congenital erythropoietic porphyria and an association with β-thalassaemia trait

The British journal of dermatology, 2012, Vol.167 (3), p.697-699

2012

Volltextzugriff (PDF)

Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity

Journal of clinical oncology, 2020-09, Vol.38 (27), p.3095-3106

2020

Volltextzugriff (PDF)

Impact of Age on the Outcomes of HCT for AML in CR1: Promising Therapy for Older Adults

Blood, 2020-11, Vol.136 (Supplement 1), p.41-42

2020

Volltextzugriff (PDF)

Icans Prophylaxis with Simvastatin and Intrathecal Dexamethasone in Adults Receiving Axicabtagene Ciloleucel (Axi‐Cel) Treatment

Blood, 2021-11, Vol.138 (Supplement 1), p.1744-1744

2021

Volltextzugriff (PDF)

Ruxolitinib Plus Nivolumab in Patients with R/R Hodgkin Lymphoma after Failure of Check-Point Inhibitors: Preliminary Report on Safety and Efficacy

Blood, 2021-11, Vol.138 (Supplement 1), p.230-230

2021

Volltextzugriff (PDF)

Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome

Blood advances, 2023-09, Vol.7 (17), p.4765-4772

2023

Volltextzugriff (PDF)

Phase II Study of Myeloablative 7-8/8-Matched Allotransplantation with Post-Transplantation Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil

Transplantation and cellular therapy, 2023-09, Vol.29 (9), p.576.e1-576.e5

2023

Volltextzugriff (PDF)

Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality

Clinical cancer research, 2023-03, Vol.29 (6), p.1114-1124

2023

Volltextzugriff (PDF)

Phase I Dose-Escalation Study of Venetoclax Plus BEAM Followed By Autologous Stem Cell Transplant (ASCT) for Chemoresistant or High-Risk Relapsed/Refractory Non-Hodgkin Lymphoma (NHL)

Blood, 2021-11, Vol.138 (Supplement 1), p.656-656

2021

Volltextzugriff (PDF)

Posttransplant Lymphoproliferative Disease Following Pancreas Transplantation: A 40 Year Single‐Center Experience

Clinical transplantation, 2024-08, Vol.38 (8), p.e15386-n/a

2024

Volltextzugriff (PDF)

Effective Cell Dose and Functional Attributes of Azercabtagene Zapreleucel (azer-cel; PBCAR0191) Associate with Allogeneic CAR T-Cell Safety and Efficacy in Patients with Relapsed/Refractory B-Cell Lymphoma

Blood, 2022-11, Vol.140 (Supplement 1), p.4588-4589

2022

Volltextzugriff (PDF)

1 – 25 von 56

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(55)
Mit Volltextzugriff
(56)

Publikationsform

Artikel
(55)
Berichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(16)
Science & Technology
(16)
Humans
(14)
Hematology
(11)
Adult
(8)
Oncology
(6)
Immunology
(5)
Lymphoma
(5)
Retrospective Studies
(5)
Transplantation
(5)
Hematopoietic Stem Cell Transplantation - Adverse Effects
(4)
Male
(4)
Middle Aged
(4)
Female
(3)
Recurrence
(3)
Aged
(2)
Cell Therapy
(2)
Child
(2)
Chronic Disease
(2)
Clinical Trials
(2)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Phase 1 trial of Ruxolitinib combined with Nivolumab in patients relapsed/refractory Hodgkin lymphoma after failure of check‐point inhibitor (CPI)

Responses after Allogeneic NK Cell Therapy for Lymphoma: correlative analysis revealed impact of host monocytes and robust T cells tumor trafficking

Leg ulcers in patients with β-thalassaemia intermedia: a single centre's experience

Intracranial blood flow velocities in patients with sickle cell disease and β‐thalassemia intermedia

PHASE I DOSE‐ESCALATION STUDY OF VENETOCLAX PLUS BEAM FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) FOR CHEMORESISTANT, RELAPSED/REFRACTORY, OR HIGH‐RISK NON‐HODGKIN'S LYMPHOMA (NHL); PRELIMINARY RESULTS

A puzzling mutation in congenital erythropoietic porphyria and an association with β-thalassaemia trait

A phase II trial of brentuximab vedotin (BV) and lenalidomide (Len) in relapsed and refractory (r/r) cutaneous (CTCL) and peripheral (PTCL) T-cell lymphomas

077 - A phase II trial of brentuximab vedotin (BV) and lenalidomide (Len) in relapsed and refractory (r/r) cutaneous (CTCL) and peripheral (PTCL) T-cell lymphomas

17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023

An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis

Cytopenias After CD19 Chimeric Antigen Receptor T-Cells (CAR-T) Therapy for Diffuse Large B-Cell Lymphomas or Transformed Follicular Lymphoma: A Single Institution Experience

A puzzling mutation in congenital erythropoietic porphyria and an association with β-thalassaemia trait

Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity

Impact of Age on the Outcomes of HCT for AML in CR1: Promising Therapy for Older Adults

Icans Prophylaxis with Simvastatin and Intrathecal Dexamethasone in Adults Receiving Axicabtagene Ciloleucel (Axi‐Cel) Treatment

Ruxolitinib Plus Nivolumab in Patients with R/R Hodgkin Lymphoma after Failure of Check-Point Inhibitors: Preliminary Report on Safety and Efficacy

Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome

Phase II Study of Myeloablative 7-8/8-Matched Allotransplantation with Post-Transplantation Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil

Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality

Phase I Dose-Escalation Study of Venetoclax Plus BEAM Followed By Autologous Stem Cell Transplant (ASCT) for Chemoresistant or High-Risk Relapsed/Refractory Non-Hodgkin Lymphoma (NHL)

Phase II Study of Myeloablative 8/8- or 7/8-Matched Allotransplantation with Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil: Marked Reduction in Gvhd Risk without Increased Relapse Risk Compared to Historical Cyclosporine/Methotrexate

Population Pharmacokinetic Model Identifies an Optimal Fludarabine Exposure for Improved Outcomes after CD19-Directed CAR T Cell Therapy for Aggressive B-NHL: Analysis from the Cell Therapy Consortium

Posttransplant Lymphoproliferative Disease Following Pancreas Transplantation: A 40 Year Single‐Center Experience

CTX110 Allogeneic CRISPR-Cas9-Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation Carbon Study

Effective Cell Dose and Functional Attributes of Azercabtagene Zapreleucel (azer-cel; PBCAR0191) Associate with Allogeneic CAR T-Cell Safety and Efficacy in Patients with Relapsed/Refractory B-Cell Lymphoma

Suchergebnisse filtern